Hangzhou Diagens Biotechnology Co., Ltd. (02526.HK)

Hangzhou Diagens Biotechnology Co., Ltd. engages in the development of medical imaging artificial intelligence (AI) technology. The company is headquartered in Hangzhou, Zhejiang. The company went IPO on 2026-03-30. The firm mainly operates through three business segments. The Medical Imaging Software and Medical Devices segment mainly sells medical imaging software and medical devices. The Technology Licensing segment mainly collects licensing fees from customers (currently including digital infrastructure service providers, research institutions, medical technology companies, and medical institutions) for using iMedImage foundation model through iMedMaaS platform. The Analysis and Consulting Services segment mainly provides consulting services to clients (mainly hospitals) based on the test results of chromosome karyotyping analysis. The firm's main products include artificial intelligence (AI) AutoVision.